DE69838179D1 - Chronische bolusgabe von d-threo methylphenidat - Google Patents
Chronische bolusgabe von d-threo methylphenidatInfo
- Publication number
- DE69838179D1 DE69838179D1 DE69838179T DE69838179T DE69838179D1 DE 69838179 D1 DE69838179 D1 DE 69838179D1 DE 69838179 T DE69838179 T DE 69838179T DE 69838179 T DE69838179 T DE 69838179T DE 69838179 D1 DE69838179 D1 DE 69838179D1
- Authority
- DE
- Germany
- Prior art keywords
- chronic
- bolusd
- threo
- attention deficit
- threo methylphenidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US937684 | 1997-09-29 | ||
US08/937,684 US5922736A (en) | 1995-12-04 | 1997-09-29 | Chronic, bolus administration of D-threo methylphenidate |
PCT/US1998/012676 WO1999016439A1 (en) | 1997-09-29 | 1998-06-17 | CHRONIC, BOLUS ADMINISTRATION OF D-threo METHYLPHENIDATE |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69838179D1 true DE69838179D1 (de) | 2007-09-13 |
DE69838179T2 DE69838179T2 (de) | 2008-04-17 |
Family
ID=25470261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69838179T Expired - Lifetime DE69838179T2 (de) | 1997-09-29 | 1998-06-17 | Chronische bolusgabe von d-threo methylphenidat |
Country Status (13)
Country | Link |
---|---|
US (11) | US5922736A (de) |
EP (2) | EP1032389B8 (de) |
AT (1) | ATE368458T1 (de) |
AU (1) | AU738521B2 (de) |
CA (2) | CA2468370C (de) |
CY (1) | CY1107748T1 (de) |
DE (1) | DE69838179T2 (de) |
DK (1) | DK1032389T3 (de) |
ES (1) | ES2289787T3 (de) |
IL (2) | IL135288A0 (de) |
NZ (1) | NZ503571A (de) |
PT (1) | PT1032389E (de) |
WO (1) | WO1999016439A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA98000395A (es) | 1995-07-14 | 2005-04-29 | Medeva Europ Ltd | Composicion que comprende d-treo-metilfenidato y otra droga. |
US6355656B1 (en) * | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
US20010055613A1 (en) * | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US6673367B1 (en) * | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
US6395752B1 (en) * | 1999-03-04 | 2002-05-28 | Pharmaquest Limited | Method of treating depression using 1-threo-methylphenidate |
GB9913458D0 (en) * | 1999-06-09 | 1999-08-11 | Medeva Europ Ltd | The therapeutic use of d-threo-methylphenidate |
AU2001286861A1 (en) * | 2000-08-28 | 2002-03-13 | Sention, Inc. | Use of methylphenidate compounds to enhance memory |
EP1315495A2 (de) * | 2000-08-28 | 2003-06-04 | Sention, Inc. | Verwendung von threo-methylphenidate-verbindungen zur erhöhung des erinnerungsvermögens |
US6855324B2 (en) * | 2000-11-20 | 2005-02-15 | Adrian Sandler | Therapeutic placebo enhancement of commonly-used medications |
US20050136106A1 (en) * | 2000-11-20 | 2005-06-23 | Adrian Sandler | Therapeutic placebo enhancement of commonly used medications |
US20020187192A1 (en) * | 2001-04-30 | 2002-12-12 | Yatindra Joshi | Pharmaceutical composition which reduces or eliminates drug abuse potential |
US20030049272A1 (en) * | 2001-08-30 | 2003-03-13 | Yatindra Joshi | Pharmaceutical composition which produces irritation |
US6638533B2 (en) * | 2002-01-03 | 2003-10-28 | George Krsek | Pulse dosage formulations of methylphenidate and method to prepare same |
ES2500117T3 (es) | 2002-02-22 | 2014-09-30 | Shire Llc | Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas |
EP1490090A4 (de) | 2002-02-22 | 2006-09-20 | New River Pharmaceuticals Inc | Wirkstoff-abgabesystem und verfahren zum schutz und zur verabreichung von wirkstoffen |
US6726624B2 (en) * | 2002-03-06 | 2004-04-27 | The Mclean Hospital Corporation | Method and apparatus for determining attention deficit hyperactivity disorder (adhd) medication dosage and for monitoring the effects of adhd medication on people who have adhd using complementary tests |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
ES2314693T3 (es) | 2004-08-23 | 2009-03-16 | PEJO ISERLOHN HEILMITTEL-UND DIAT-GMBH & CO.KG | Composicion farmaceutica que contiene psicoestimulantes. |
US20060127421A1 (en) * | 2004-12-09 | 2006-06-15 | Celgene Corporation | Treatment using D-threo methylphenidate |
US20060183773A1 (en) * | 2005-01-20 | 2006-08-17 | David Bar-Or | Uses of methylphenidate derivatives |
NZ556456A (en) | 2005-01-20 | 2010-12-24 | Inst Molecular Medicine Inc | Methylphenidate derivatives and uses of them |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
WO2008011596A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
US20090076079A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched methylphenidate |
US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
CA2830788C (en) | 2011-03-23 | 2016-05-17 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
JP2023553202A (ja) | 2020-12-08 | 2023-12-20 | ルミナント バイオテク コーポレーション リミテッド | 動物に物質を送達するための装置および方法の改善 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US32335A (en) * | 1861-05-14 | Island | ||
US19535A (en) * | 1858-03-02 | Improvement in sewing-machines | ||
US49205A (en) * | 1865-08-01 | Improvement in machines for hulling grain | ||
US105134A (en) * | 1870-07-05 | Thomas sheehan | ||
US2507631A (en) * | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
US2738303A (en) * | 1952-07-18 | 1956-03-13 | Smith Kline French Lab | Sympathomimetic preparation |
US2838519A (en) * | 1953-12-23 | 1958-06-10 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
US2957880A (en) * | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
US3048526A (en) * | 1958-08-04 | 1962-08-07 | Wander Company | Medicinal tablet |
US3365365A (en) * | 1965-08-09 | 1968-01-23 | Hoffmann La Roche | Repeat action pharmaceutical compositions in the form of discrete beadlets |
US4137300A (en) * | 1976-08-20 | 1979-01-30 | Ciba-Geigy Corporation | Sustained action dosage forms |
US4410700A (en) * | 1980-07-03 | 1983-10-18 | The United States Of America As Represented By The Department Of Health And Human Services | Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution |
DE3279999D1 (en) * | 1981-09-30 | 1989-11-30 | Nat Res Dev | Compositions comprising encapsulated particles |
US4728512A (en) * | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4904476A (en) * | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) * | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US4986987A (en) * | 1986-05-09 | 1991-01-22 | Alza Corporation | Pulsed drug delivery |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5114946A (en) * | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US5283193A (en) * | 1988-06-27 | 1994-02-01 | Asahi Kasei Kogyo K.K. | Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor |
SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5217718A (en) * | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5284769A (en) * | 1989-10-16 | 1994-02-08 | Chiros Ltd. | Process for preparing a single enantiomer of a lactam using lactamase |
US5362755A (en) * | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
US5158777A (en) * | 1990-02-16 | 1992-10-27 | E. R. Squibb & Sons, Inc. | Captopril formulation providing increased duration of activity |
JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
US5104899A (en) * | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
US5232705A (en) * | 1990-08-31 | 1993-08-03 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
US5156850A (en) * | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
JPH04230625A (ja) * | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法 |
US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
KR100205276B1 (ko) * | 1991-10-04 | 1999-07-01 | 가마쿠라 아키오 | 서방성 정제 |
EP0546593B1 (de) * | 1991-10-30 | 1997-09-03 | Glaxo Group Limited | Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
US5299121A (en) * | 1992-06-04 | 1994-03-29 | Medscreen, Inc. | Non-prescription drug medication screening system |
US5512293A (en) * | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
DK0701443T4 (da) * | 1992-08-03 | 2000-12-18 | Sepracor Inc | Terfenadinmetabolitter og deres optisk rene isomerer til behandling af allergiske lidelser |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
JP3091618B2 (ja) * | 1993-01-29 | 2000-09-25 | 四郎 小林 | 開環重合法および開環重合用酵素触媒 |
US5784090A (en) * | 1993-04-30 | 1998-07-21 | Hewlett-Packard Company | Use of densitometer for adaptive control of printer heater output to optimize drying time for different print media |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5387284A (en) * | 1994-03-07 | 1995-02-07 | James River Paper Company, Inc. | Apparatus and method for forming coreless paper roll products |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
GB9514451D0 (en) * | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
JPH11509227A (ja) * | 1995-07-14 | 1999-08-17 | カイロサイエンス・リミテッド | d−トレオ−メチルフェニデートの治療的使用 |
MXPA98000395A (es) * | 1995-07-14 | 2005-04-29 | Medeva Europ Ltd | Composicion que comprende d-treo-metilfenidato y otra droga. |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6355656B1 (en) * | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5733756A (en) * | 1996-01-05 | 1998-03-31 | Celgene Corporation | Lactams and processes for stereoselective enrichment of lactams, amides, and esters |
US6242464B1 (en) * | 1996-01-22 | 2001-06-05 | Chiroscience Limited | Single isomer methylphenidate and resolution process |
DK0879228T3 (da) * | 1996-02-02 | 2003-03-03 | Medeva Europ Ltd | Fremgangsmåde til fremstilling af d-threo-(R,R)-methylphenidat og recirkulering af uønskede enantiomerer ved epimerisering |
GB9604943D0 (en) * | 1996-03-08 | 1996-05-08 | Chiroscience Ltd | Resolution |
GB9606417D0 (en) * | 1996-03-27 | 1996-06-05 | Chiroscience Ltd | Asymmetric cyclisation |
US5733478A (en) * | 1996-09-24 | 1998-03-31 | Gowan Company | Method and composition for reducing the degradation rate of agrochemicals in storage |
ES2264173T3 (es) | 1996-11-25 | 2006-12-16 | Alza Corporation | Forma de dosificacion para suministrar una dosis creciente. |
GB9700912D0 (en) * | 1997-01-17 | 1997-03-05 | Chiroscience Ltd | Resolution |
US5965734A (en) * | 1997-01-31 | 1999-10-12 | Celgene Corporation | Processes and intermediates for preparing 2-substituted piperidine stereoisomers |
US5936091A (en) * | 1997-05-22 | 1999-08-10 | Celgene Corporation | Processes and intermediates for resolving piperidyl acetamide stereoisomers |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
NZ511442A (en) * | 1998-11-02 | 2003-02-28 | Elan Corp Plc | Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl |
US6127385A (en) * | 1999-03-04 | 2000-10-03 | Pharmaquest Limited | Method of treating depression using l-threo-methylphenidate |
US6395752B1 (en) * | 1999-03-04 | 2002-05-28 | Pharmaquest Limited | Method of treating depression using 1-threo-methylphenidate |
AU4334700A (en) * | 1999-04-06 | 2000-10-23 | Shubha Chungi | Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
US6221883B1 (en) * | 2000-04-12 | 2001-04-24 | Ross Baldessarini | Method of dopamine inhibition using l-threo-methylphenidate |
US20020132793A1 (en) * | 2000-08-28 | 2002-09-19 | Mel Epstein | Use of methylphenidate compounds to enhance memory |
EP1315495A2 (de) * | 2000-08-28 | 2003-06-04 | Sention, Inc. | Verwendung von threo-methylphenidate-verbindungen zur erhöhung des erinnerungsvermögens |
US6344215B1 (en) * | 2000-10-27 | 2002-02-05 | Eurand America, Inc. | Methylphenidate modified release formulations |
US6359139B1 (en) * | 2000-11-07 | 2002-03-19 | Celgene Corporation | Methods for production of piperidyl acetamide stereoisomers |
-
1997
- 1997-09-29 US US08/937,684 patent/US5922736A/en not_active Expired - Lifetime
-
1998
- 1998-06-17 EP EP98930358A patent/EP1032389B8/de not_active Expired - Lifetime
- 1998-06-17 ES ES98930358T patent/ES2289787T3/es not_active Expired - Lifetime
- 1998-06-17 AT AT98930358T patent/ATE368458T1/de active
- 1998-06-17 NZ NZ503571A patent/NZ503571A/xx not_active IP Right Cessation
- 1998-06-17 WO PCT/US1998/012676 patent/WO1999016439A1/en active Search and Examination
- 1998-06-17 EP EP07014078A patent/EP1844777A1/de not_active Withdrawn
- 1998-06-17 AU AU79765/98A patent/AU738521B2/en not_active Expired
- 1998-06-17 PT PT98930358T patent/PT1032389E/pt unknown
- 1998-06-17 DE DE69838179T patent/DE69838179T2/de not_active Expired - Lifetime
- 1998-06-17 DK DK98930358T patent/DK1032389T3/da active
- 1998-06-17 IL IL13528898A patent/IL135288A0/xx active IP Right Grant
- 1998-06-22 CA CA002468370A patent/CA2468370C/en not_active Expired - Lifetime
- 1998-06-22 CA CA002241611A patent/CA2241611C/en not_active Expired - Lifetime
-
1999
- 1999-06-21 US US09/337,310 patent/US6255325B1/en not_active Expired - Lifetime
-
2000
- 2000-03-27 IL IL135288A patent/IL135288A/en not_active IP Right Cessation
-
2001
- 2001-05-24 US US09/864,617 patent/US6602887B2/en not_active Expired - Lifetime
-
2003
- 2003-03-24 US US10/395,444 patent/US20030232857A1/en not_active Abandoned
-
2004
- 2004-10-08 US US10/961,122 patent/US20050119307A1/en not_active Abandoned
- 2004-10-12 US US10/963,460 patent/US20050049279A1/en not_active Abandoned
-
2005
- 2005-10-06 US US11/244,924 patent/US20060030587A1/en not_active Abandoned
-
2007
- 2007-10-02 CY CY20071101250T patent/CY1107748T1/el unknown
-
2008
- 2008-12-09 US US12/331,127 patent/US20090088455A1/en not_active Abandoned
-
2009
- 2009-10-16 US US12/580,800 patent/US20100035928A1/en not_active Abandoned
-
2011
- 2011-04-26 US US13/093,917 patent/US20110201645A1/en not_active Abandoned
-
2012
- 2012-12-20 US US13/721,224 patent/US20130109719A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1032389B8 (de) | 2008-05-28 |
US20060030587A1 (en) | 2006-02-09 |
US6602887B2 (en) | 2003-08-05 |
EP1032389B1 (de) | 2007-08-01 |
ATE368458T1 (de) | 2007-08-15 |
DE69838179T2 (de) | 2008-04-17 |
CA2241611A1 (en) | 1999-03-29 |
US6255325B1 (en) | 2001-07-03 |
US20130109719A1 (en) | 2013-05-02 |
US20010041717A1 (en) | 2001-11-15 |
CY1107748T1 (el) | 2013-04-18 |
IL135288A (en) | 2007-06-03 |
AU738521B2 (en) | 2001-09-20 |
US5922736A (en) | 1999-07-13 |
AU7976598A (en) | 1999-04-23 |
US20100035928A1 (en) | 2010-02-11 |
US20110201645A1 (en) | 2011-08-18 |
EP1032389A1 (de) | 2000-09-06 |
US20050119307A1 (en) | 2005-06-02 |
CA2468370C (en) | 2009-02-24 |
US20090088455A1 (en) | 2009-04-02 |
EP1844777A1 (de) | 2007-10-17 |
US20030232857A1 (en) | 2003-12-18 |
ES2289787T3 (es) | 2008-02-01 |
CA2468370A1 (en) | 1999-03-29 |
PT1032389E (pt) | 2007-09-05 |
CA2241611C (en) | 2004-08-17 |
WO1999016439A1 (en) | 1999-04-08 |
US20050049279A1 (en) | 2005-03-03 |
IL135288A0 (en) | 2001-05-20 |
NZ503571A (en) | 2003-04-29 |
EP1032389A4 (de) | 2002-07-03 |
DK1032389T3 (da) | 2007-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69838179D1 (de) | Chronische bolusgabe von d-threo methylphenidat | |
DE69830513D1 (de) | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN | |
DE69715786D1 (de) | Zusammensetzungen mit kationischen amphiphilen und colipiden zur intrazellulären verabreichung therapeutischer moleküle | |
ATE412642T1 (de) | Inhibitoren von p-38-kinase | |
DE69427704T2 (de) | Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane | |
DK2145627T3 (da) | Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse. | |
DE69429527D1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
DE69931789D1 (de) | Behandlung von nicotinsucht und sucht bedingtem verhalten | |
ATE361089T1 (de) | Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin | |
ATE271865T1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
DE69621799D1 (de) | Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen | |
BR0201862A (pt) | Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos | |
DE69821498D1 (de) | Verwendung von amifostin | |
DE68925004T2 (de) | Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen. | |
HUP0100611A2 (hu) | Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére | |
DK0871446T3 (da) | Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen | |
DE69621786D1 (de) | Aminotetralinderivat zur behandlung von herzkreislauferkrankung | |
CY1108050T1 (el) | Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων | |
ATE324881T1 (de) | Antagonisten der defektiven magnesiumbindung als therapeutische mittel und methoden zur behandlung von abnormalen physiologischen zuständen | |
BR0210678A (pt) | Carbamatos de 2-heterocìclicos-1,2-etanodióis | |
WO2004100899A3 (en) | Use of secretin in treatments of disorders associated with the amygdala | |
DE500713T1 (de) | Derivate des 3,3,5-trimethylcyclohexylesters von 2-methylpropionsaeure, ihr herstellungsverfahren sowie diese enthaltende therapeutische kompositionen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: CELGENE CORP., SUMMIT, N.J., US |
|
8364 | No opposition during term of opposition |